Safety Profile
Known Safety Concerns
- Raises blood glucose -- relevant for diabetics
- Should not replace antibiotic treatment for complicated UTIs
- Higher doses cause osmotic diarrhoea
- Very large doses may be gluconeogenic
Contraindications
- Raises blood glucose -- relevant for diabetics
- Should not replace antibiotic treatment for complicated UTIs
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
D-mannose is a simple sugar used for urinary tract infection (UTI) prevention and recurrence reduction. It inhibits E. coli adhesion to urinary tract epithelium. Clinical evidence for prevention of recurrent UTIs is moderately positive. Raises blood glucose. Should not replace antibiotic treatment for active UTI in high-risk individuals.
Biological and Chemical Classification
- Scientific Name
- D-Mannose
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Metabolic
- Evidence consistency: High consistency across studies (100%)
- Raises blood glucose -- relevant for diabetics
- Should not replace antibiotic treatment for complicated UTIs
- Higher doses cause osmotic diarrhoea
- Very large doses may be gluconeogenic
The available scientific evidence for D-Mannose indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 17:57
Evidence Distribution
-
Observational / other LOW evidence YELLOWDevelopment of a cold-adapted enzymatic cascade system for in situ value-added conversion of milk. ↗Zeng Q et al.. Development of a cold-adapted enzymatic cascade system for in situ value-added conversion of milk.. Food Chem. 2026. PMID:41871497.PMID 41871497 ↗Journal Food ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41871497/
-
Observational / other LOW evidence YELLOWSynthesis of 3u2011Cu2011Methylu2011du2011Mannopyranoside Derivatives Functionalized at the 3u2011Position. ↗Abdullayev S et al.. Synthesis of 3u2011Cu2011Methylu2011du2011Mannopyranoside Derivatives Functionalized at the 3u2011Position.. ACS Omega. 2026. PMID:41799092.PMID 41799092 ↗Journal ACS OmegaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41799092/
-
Observational / other LOW evidence YELLOWBrain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy. ↗Patel S et al.. Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy.. Brain Res. 2026. PMID:41791502.PMID 41791502 ↗Journal Brain ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41791502/
-
Observational / other LOW evidence YELLOWSporolactobacillus fermentans sp. nov., an obligately anaerobic and lactic acid bacterium isolated from pit mud. ↗Ye G et al.. Sporolactobacillus fermentans sp. nov., an obligately anaerobic and lactic acid bacterium isolated from pit mud.. Antonie Van Leeuwenhoek. 2026. PMID:41770425.PMID 41770425 ↗Journal Antonie Van LeeuwenhoekYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41770425/
-
Observational / other LOW evidence YELLOWTissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability. ↗Onluturk Aydogan O et al.. Tissue-Specific Multi-Omics Integration Demonstrates Molecular Signatures Connecting Obesity to Immune Vulnerability.. Metabolites. 2026. PMID:41745578.PMID 41745578 ↗Journal MetabolitesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41745578/
-
Observational / other LOW evidence YELLOWA randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women. ↗Singh RG et al.. A randomized, triple-blind, placebo-controlled, parallel study of the efficacy of D-mannose for urinary tract infection symptoms in women.. Curr Urol. 2026. PMID:41743922.PMID 41743922 ↗Journal Curr UrolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41743922/
-
Observational / other LOW evidence YELLOWSynthesis of N-substituted 2-carboxamido azasugars via sequential Ugi-3CR/cyclization reaction. ↗Luo H et al.. Synthesis of N-substituted 2-carboxamido azasugars via sequential Ugi-3CR/cyclization reaction.. Carbohydr Res. 2026. PMID:41723923.PMID 41723923 ↗Journal Carbohydr ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41723923/
-
Observational / other LOW evidence YELLOWMicroplastics and Nitrite Stress Affect Physiological and Metabolic Functions of the Hepatopancreas in Marine Shrimp. ↗Xing YF et al.. Microplastics and Nitrite Stress Affect Physiological and Metabolic Functions of the Hepatopancreas in Marine Shrimp.. J Xenobiot. 2026. PMID:41718265.PMID 41718265 ↗Journal J XenobiotYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41718265/
-
Observational / other LOW evidence YELLOWThe responses of rice plant to tricyclazole at the transcriptome and metabolome levels. ↗Huang W et al.. The responses of rice plant to tricyclazole at the transcriptome and metabolome levels.. Front Plant Sci. 2026. PMID:41710179.PMID 41710179 ↗Journal Front Plant SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41710179/
-
Observational / other LOW evidence YELLOWPrimary Care Provider Practice Patterns in the Management of Recurrent UTI. ↗Tholemeier LN et al.. Primary Care Provider Practice Patterns in the Management of Recurrent UTI.. Urogynecology (Phila). 2025. PMID:41811789.PMID 41811789 ↗Journal Urogynecology (Phila)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41811789/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for D-Mannose. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for D-Mannose
A score of 2.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.